NASDAQ:OMER Omeros (OMER) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free OMER Stock Alerts $3.45 +0.03 (+0.88%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.36▼$3.5150-Day Range$3.24▼$4.8952-Week Range$0.92▼$7.80Volume331,192 shsAverage Volume593,240 shsMarket Capitalization$216.90 millionP/E Ratio10.78Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Omeros alerts: Email Address Omeros MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish22.55% of Float Sold ShortDividend StrengthN/ASustainability-1.30Upright™ Environmental ScoreNews Sentiment0.51Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.30) to ($2.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector700th out of 938 stocksPharmaceutical Preparations Industry317th out of 425 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Omeros. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.55% of the float of Omeros has been sold short.Short Interest Ratio / Days to CoverOmeros has a short interest ratio ("days to cover") of 21.5, which indicates bearish sentiment.Change versus previous monthShort interest in Omeros has recently decreased by 1.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOmeros does not currently pay a dividend.Dividend GrowthOmeros does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOmeros has received a 67.78% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Omeros is -1.30. Previous Next 2.5 News and Social Media Coverage News SentimentOmeros has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Omeros this week, compared to 2 articles on an average week.Search Interest5 people have searched for OMER on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omeros insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Omeros are expected to grow in the coming year, from ($2.30) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omeros is 10.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Omeros is 10.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 220.56.Price to Book Value per Share RatioOmeros has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Omeros Stock (NASDAQ:OMER)Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Read More OMER Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMER Stock News HeadlinesMarch 27, 2024 | businesswire.comOmeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024March 27, 2024 | americanbankingnews.comOmeros (NASDAQ:OMER) Downgraded to "Sell" at StockNews.comMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 26, 2024 | americanbankingnews.comOmeros (NASDAQ:OMER) Share Price Passes Above 200-Day Moving Average of $2.96March 19, 2024 | finance.yahoo.comOMER Aug 2024 3.000 putMarch 3, 2024 | finance.yahoo.comOMER Aug 2024 5.000 putMarch 1, 2024 | gurufocus.comOmeros Corporation - Special Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2020 Omeros Corp Earnings Call TranscriptMarch 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 1, 2024 | gurufocus.comOmeros Corp at JPMorgan Healthcare Conference (Virtual) TranscriptMarch 1, 2024 | gurufocus.comQ4 2020 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp at Bank of America NAPA Healthcare Conference (Virtual) TranscriptMarch 1, 2024 | gurufocus.comQ2 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp Regulatory Update Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp Omidria Call TranscriptMarch 1, 2024 | gurufocus.comQ4 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ2 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ4 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2023 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ2 2023 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp To Provide Data Update Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2023 Omeros Corp Earnings Call TranscriptFebruary 27, 2024 | wsj.comOmeros Corp.See More Headlines Receive OMER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/28/2024Next Earnings (Confirmed)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OMER CUSIP68214310 CIK1285819 Webwww.omeros.com Phone(206) 676-5000Fax206-676-5005Employees196Year Founded1994Profitability EPS (Most Recent Fiscal Year)$0.32 Trailing P/E Ratio10.69 Forward P/E RatioN/A P/E GrowthN/ANet Income$47.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-493.77% Return on Assets-33.47% Debt Debt-to-Equity Ratio10.80 Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book2.50Miscellaneous Outstanding Shares62,870,000Free Float56,013,000Market Cap$215.02 million OptionableOptionable Beta1.38 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Gregory A. Demopulos M.D. (Age 65)Co-Founder, Chairman, CEO & President Comp: $1.79MMr. Michael A. Jacobsen (Age 66)Chief Accounting Officer, VP of Finance & Treasurer Comp: $518.6kMr. Peter B. Cancelmo J.D. (Age 45)VP, General Counsel & Corporate Secretary Comp: $503.24kDr. Pamela Pierce Palmer M.D. (Age 61)Ph.D., Co-Founder Dr. George A. Gaitanaris M.D. (Age 67)Ph.D., Chief Scientific Officer & VP of Science Mr. Peter W. Williams (Age 56)Vice President of Human Resources Dr. Catherine A. Melfi Ph.D. (Age 65)Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems Ms. Nadia Dac (Age 54)VP & Chief Commercial Officer Dr. Andreas Grauer M.D. (Age 63)Chief Medical Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRAssembly BiosciencesNASDAQ:ASMBMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDAOvid TherapeuticsNASDAQ:OVIDView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Sold 62,338 shares on 3/27/2024Ownership: 0.609%Vanguard Group Inc.Bought 26,085 shares on 3/11/2024Ownership: 5.040%Goldman Sachs Group Inc.Sold 64,645 shares on 3/1/2024Ownership: 0.067%Virtu Financial LLCBought 29,074 shares on 2/26/2024Ownership: 0.046%Wolverine Trading LLCSold 5,400 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions OMER Stock Analysis - Frequently Asked Questions Should I buy or sell Omeros stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares. View OMER analyst ratings or view top-rated stocks. How have OMER shares performed in 2024? Omeros' stock was trading at $3.27 on January 1st, 2024. Since then, OMER shares have increased by 5.5% and is now trading at $3.45. View the best growth stocks for 2024 here. When is Omeros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our OMER earnings forecast. How can I listen to Omeros' earnings call? Omeros will be holding an earnings conference call on Monday, April 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. The biopharmaceutical company had revenue of $30 million for the quarter, compared to analyst estimates of $29.31 million. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. What is Gregory A. Demopulos' approval rating as Omeros' CEO? 17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees. What other stocks do shareholders of Omeros own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX). Who are Omeros' major shareholders? Omeros' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.04%), Vanguard Group Inc. (5.04%), Stifel Financial Corp (3.01%), Corient Private Wealth LLC (1.06%), Northern Trust Corp (0.89%) and Royal Bank of Canada (0.81%). Insiders that own company stock include Arnold C Hanish, Gregory A Md Demopulos and Peter A Md Demopulos. View institutional ownership trends. How do I buy shares of Omeros? Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Omeros have any subsidiaries? The following companies are subsidiares of Omeros: Nura.Read More This page (NASDAQ:OMER) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.